Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Schedules,Therapeutic_group
Amgen,Carfilzomib,relapsed or refractory multiple myeloma,Carfilzomib,,Oncology Agents and Immunosuppressants
